Search Results

You are looking at 241 - 250 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

Featured Updates to the NCCN Guidelines

Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson Jr, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, and Shaji K. Kumar

variety of therapies are available for previously treated MM. The choice of appropriate therapy for a patient depends on the context of the clinical relapse, such as prior treatment, duration of response, the class of agents previously received, and

Full access

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Featured Updates to the NCCN Guidelines

Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, and Martin S. Tallman

. Current pretreatment factors, such as age, cytogenetics, and the presence of specific gene mutations, are used to estimate posttreatment risk of relapse. 6 – 8 Increasing evidence suggests that the evaluation of measurable or minimal residual disease (MRD

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Featured Updates to the NCCN Guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller, and Rashmi Kumar

Previously Treated MM A variety of therapies continue to be listed as options for previously treated MM. The choice of appropriate therapy for a patient would depend on the context of clinical relapse, such as prior treatment and duration of response. New

Full access

Guidelines for NHL: Updates to the Management of Diffuse Large B-Cell Lymphoma and New Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders and T-Cell Large Granular Lymphocytic Leukemia

Andrew D. Zelenetz

of lenalidomide for non-GCB subtype 9 and ibrutinib (Bruton tyrosine kinase inhibitor) for the ABC subtype of relapsed/refractory DLBCL. 10 In a retrospective review of 44 patients with relapsed/refractory DLBCL, a significant difference in

Full access

New Therapies for Ovarian Cancer

David M. O’Malley

fairly complex,” Dr. O’Malley acknowledged. Platinum-sensitive disease refers to patients who achieve complete remission and experience relapse ≥6 months after completing prior chemotherapy. Options for patients with radiographic or clinical relapse

Full access

Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment

Presented by: Stephen D. Smith

patients if surgical treatment is successful, said Dr. Smith. For advanced or relapsed/refractory disease, chemoimmunotherapy has been demonstrated to improve outcomes more than chemotherapy alone. This therapy can also be delivered in a shortened format

Full access

Advances in the Management of Classical Hodgkin Lymphoma

Presented by: Ryan C. Lynch

Management “It has been very busy…in the HL field,” Dr. Lynch remarked. Although brentuximab vedotin, nivolumab, and pembrolizumab were initially approved as monotherapies in the relapsed setting, he emphasized, “We have learned a lot…about how to utilize

Full access

Acute Myeloid Leukemia

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Salil Goorha, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, Eunice S. Wang, Maoko Naganuma, and Kristina M. Gregory

outcomes in patients with therapy-related AML have been shown to be significantly inferior (both in terms of relapse-free and overall survivals) compared with patients with de novo cases, 7 , 14 except those with the therapy-related acute promyelocytic

Full access

New NCCN Guidelines for Vulvar Cancer

Benjamin E. Greer and Wui-Jin Koh

resected groins with positive lymph nodes, leading to improved relapse-free and overall survivals, Dr. Koh said. Nodal involvement at presentation is the strongest independent predictor of relapse. “Chemotherapy given concurrently with radiation may

Full access

Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers

Alison R. Walker and Guido Marcucci

consistently demonstrated. Internal tandem duplications (ITDs) of the FLT3 gene occur in 25% to 35% of patients with CN-AML and confer an increased risk for relapse and death when compared with patients without FLT3 -ITD. 7 - 9 It seems that not only the